A double-blind, randomized, placebo-controlled, phase I/Iib clinical trial using nemolizumab was performed in humans and revealed that the anti–IL-31 antibody improves the clinical symptoms and decreases pruritus associated with AD [130,131]. Here, IL31 is linked to Pruritus.